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Inhibition of IFN- Signaling
by an Epstein-Barr Virus Immediate-Early Protein
immune responses. However, cell-mediated responses
are believed to be more important in the control of EBV
infection (Cohen, 2000). Elevated levels of activated
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sion have been observed in tonsil sections from IM pa-
tients (Andersson et al., 1994). However, EBV estab-
lishes a life-long relationship with the infected person,Summary
maintaining a persistent latent infection within the B
cell population, and undergoing periodic spontaneousViruses have evolved elaborate mechanisms to target
reactivation resulting in lytic replication, reinfection ofmany aspects of the host’s immune response. The
the oral epithelium, and shedding of virus into the salivacytokine IFN- plays a central role in resistance of the
(Cohen, 2000: Kieff, 1996; Rickinson and Kieff, 1996).host to infection via direct antiviral effects as well as
This suggests that the virus has evolved mechanismsmodulation of the immune response. In this study, we
to evade host immune system responses.demonstrate that the Epstein-Barr virus (EBV) immedi-
Primary infection by viruses is countered initially byate-early protein, BZLF1, inhibits the IFN- signaling
the host’s innate immune responses, followed by adap-pathway. BZLF1 decreases the ability of IFN- to acti-
tive-immune responses. Components of the innate re-vate a variety of important downstream target genes,
sponse include phagocytic cells, natural killer cells, andsuch as IRF-1, p48, and CIITA, and prevents IFN--
cytokines such as the interferons. Adaptive responsesinduced class II MHC surface expression. Additionally,
involve proliferation of antigen-specific T cells and BBZLF1 inhibits IFN--induced STAT1 tyrosine phos-
cells. As part of innate and adaptive immune responses,phorylation and nuclear translocation. Finally, we
the type I (IFN-/) and type II (IFN-) interferons aredemonstrate that BZLF1 decreases expression of the
major lines of defense against viral infection. IFN-/IFN- receptor, suggesting a mechanism by which
and IFN- induce expression of cellular proteins, suchEBV may escape antiviral immune responses during
as protein kinase R and 2-5-oligoadenylate synthetase,primary infection.
which elicit direct antiviral effects (Boehm et al., 1997;
Stark et al., 1998). IFN-/ and IFN- both upregulateIntroduction
MHC class I expression. In addition, IFN- strongly in-
duces MHC class II expression on non-APC cells suchEpstein-Barr virus (EBV) is a ubiquitous human  herpes-
as endothelial cells and fibroblasts (Collins et al., 1984;virus that is the causative agent of infectious mononu-
Pober et al., 1983). IFN-/ is produced by virally in-cleosis (IM) (Kieff, 1996; Rickinson and Kieff, 1996). EBV
fected cells, whereas IFN- is produced by immune sys-is also associated with several B cell and epithelial cell
tem cells that function in early immune responses suchmalignancies, including Burkitt’s lymphoma and naso-
as natural killer cells, natural killer T cells, and / Tpharyngeal carcinoma (Rickinson and Kieff, 1996). Dur-
cells, as well as immune system cells activated during
ing primary infection, EBV initially undergoes lytic repli-
adaptive responses such as Th1 cells and CD8 cells
cation in the oropharyngeal epithelium (Cohen 2000;
(Biron, 1999).
Kieff, 1996; Li et al., 1992; Sixby et al., 1984). The virus Viruses have evolved elaborate strategies to evade
subsequently infects trafficking B cells where it converts detection and destruction by host immune responses,
to a latent infection. Lytic replication is initiated by the including targeting pathways for antigen presentation,
expression of two immediate-early (IE) genes, BZLF1 programmed cell death, and cytokine- and chemokine-
and BRLF1 (Chevallier-Greco et al., 1986; Countryman mediated signaling (Tortorella et al., 2000). There is in-
and Miller, 1985; Ragoczy et al., 1998; Rooney et al., creasing evidence that lytic cycle proteins of herpesvi-
1989; Takada et al., 1986; Urier et al., 1989; Zalani et ruses play a role in evading host immune responses,
al., 1996). The protein products of BZLF1 and BRLF1 including disruption of interferon signaling. For example,
function as transcriptional transactivators and induce cytomegalovirus (human and murine) (Heise et al., 1998;
the lytic cascade of viral gene expression (Chang et al., Miller et al., 1998; Sedmak et al., 1994) and Varicella-
1990; Cox et al., 1985; Flemington and Speck, 1990, Zoster virus (VZV) (Abendroth et al., 2000) lytic cycle
Flemington et al., 1992; Hardwick et al., 1988, 1992; proteins inhibit IFN--induced MHC class II expression.
Holley-Guthrie et al., 1990; Kenney et al., 1989; Lieber- In addition, Kaposi’s sarcoma-associated herpesvirus
man et al., 1989; Quinlivan et al., 1993; Rooney et al., (KSHV) encodes lytic viral proteins which are viral inter-
1989). feron response factor (vIRF) homologs and interfere with
Infection by EBV results in both humoral and cellular interferon signal transduction and subsequent gene
transactivation (Gao et al., 1997: Li et al., 1998; Zimring
et al., 1998).5 Correspondence: shann@med.unc.edu
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In the present study, we have examined the ability of cally recognizes the tyrosine-phosphorylated form of
STAT1, we observed by immunoblot analysis that IFN-the EBV immediate-early proteins to disrupt cell signal-
ing pathways activated by IFN-. Binding of IFN- to treatment induces STAT1 tyrosine phosphorylation in
mock-infected and AdlacZ-infected cells. In contrast,its cell surface receptor initiates a signal transduction
cascade which involves tyrosine phosphorylation of the IFN--induced STAT1 tyrosine phosphorylation is sig-
nificantly decreased in AdZ-infected cells. However,receptor-associated Janus kinases (Jaks) Jak1 and
Jak2, followed by tyrosine phosphorylation of STAT1 BZLF1 expression in HeLa and A549 cells does not affect
the total level of STAT1. Thus, the inhibition of IFN--(Bach et al., 1997). Phosphorylated STAT1 molecules
subsequently form homodimers, translocate to the nu- induced gene expression by BZLF1 is due to a defect
in the IFN- signaling pathway that lies upstream ofcleus, bind -activated sequence (GAS) elements, and
upregulate the expression of IFN--inducible genes. STAT1 tyrosine phosphorylation.
BZLF1 has been previously reported to inhibit STATHere, we report that expression of BZLF1 inhibits IFN-
induction of a variety of important downstream target activation of the EBV BamH1-Q promoter in a p53-
dependent manner (Chen et al., 1999). Therefore, wegenes including class II MHC surface expression. Ex-
pression of BZLF1 but not BRLF1 inhibits IFN--induced investigated whether BZLF1 inhibits IFN--induced
STAT1 tyrosine phosphorylation in p53-deleted Saos-2STAT1 tyrosine phosphorylation. We demonstrate that
the transactivation and the DNA binding domains of cells (Figure 2D). IFN--induced STAT1 tyrosine phos-
phorylation in AdZ-infected Saos-2 cells was inhibited,BZLF1 are required for inhibition of IFN--induced
STAT1 nuclear translocation. Finally, we show that in contrast to mock-infected and AdlacZ-infected cells.
The total levels of STAT1 were similar in all groups.BZLF1 abrogates cellular responses to IFN- by de-
creasing expression of the IFN- receptor. Our results Therefore, the ability of BZLF1 to inhibit STAT1 tyrosine
phosphorylation induced by IFN- is a p53-independentsuggest a mechanism by which EBV may escape early
antiviral immune responses during primary infection. process.
BZLF1 Does Not Inhibit IFN--Induced STAT1Results
Tyrosine Phosphorylation
IFN- induces tyrosine phosphorylation of STAT1 byBZLF1 Inhibits IFN--Induced Gene Expression
IFN- exerts a wide range of biological effects by activat- activating the Jak kinases Tyk2 and Jak1 associated
with the cytoplasmic tails of the IFN-R1 and IFN-R2ing a Jak-STAT signaling pathway and inducing expres-
sion of cellular genes (Bach et al., 1997; Boehm et al., subunits, respectively (Stark et al., 1998). We examined
whether the inhibition of STAT1 tyrosine phosphoryla-1997). To investigate whether BZLF1 disrupts IFN--
induced gene expression, we used a replication-defi- tion by BZLF1 (Figure 2) is specific to that induced by
IFN- or if other signaling pathways leading to STAT1cient adenovirus vector (AdZ) to express the BZLF1 pro-
tein or the LacZ protein (AdlacZ) in HeLa cells and the tyrosine phosphorylation might also be affected. In con-
trast to its effect on IFN- signaling, expression of BZLF1lung carcinoma cell line A549 using a moi of 50 (Figure
1). HeLa cells infected with AdZ at a moi of 50 express in HeLa cells does not significantly alter STAT1 tyrosine
phosphorylation induced by IFN- (Figure 3A).BZLF1 at a similar level as the lytically infected popula-
tion of EBV-positive AGS gastric carcinoma cells (Figure We also investigated the ability of the other EBV imme-
diate-early protein, BRLF1, to inhibit IFN-- or IFN--1A). In mock-infected and AdlacZ-infected HeLa and
A549 cells (moi of 50), IFN- treatment induced expres- induced STAT1 tyrosine phosphorylation. IFN- and
IFN- both effectively induced STAT1 tyrosine phos-sion of both IRF-1 and p48 (Figure 1B), which are mem-
bers of the Interferon Regulatory Factor (IRF) family of phorylation in HeLa cells infected with an adenovirus
vector expressing the BRLF1 protein (Figure 3B). In addi-proteins (Nguyen et al., 1997). In contrast, IFN--induced
IRF-1 and p48 expression was significantly decreased tion, expression of BRLF1 did not affect IFN- induction
of IRF-1 (Figure 3B).in cells infected with AdZ. A control transcription factor
(the p65 component of NF-B) was not affected by IFN-
or AdZ. These results suggest that BZLF1 expression Inhibition of IFN- Signaling by BZLF1 Requires
interferes with some aspect of IFN- signaling. the Transactivation and DNA Binding Domains
The BZLF1 protein has transcriptional transactivation,
DNA binding, and dimerization domains (Flemington etBZLF1 Inhibits IFN--Induced STAT1
Tyrosine Phosphorylation al., 1992; Kouzarides et al., 1991; Packham et al., 1990).
In order to determine the domains of BZLF1 requiredIFN- induces tyrosine phosphorylation of latent STAT1
molecules in the cell cytoplasm (Decker et al., 1991; for inhibition of IFN- signaling, we expressed various
BZLF1 wild-type and mutant plasmids (Figure 4A) inShuai et al., 1992, 1993). Once phosphorylated on tyro-
sine, STAT1 molecules form homodimers, translocate HeLa cells and examined the effect on STAT1 nuclear
translocation after treatment with IFN- (Figure 4B).to the nucleus, and activate transcription of cellular
genes by binding to specific DNA elements known as STAT1 staining of untreated cells transfected with the
vector control is distinctly cytoplasmic (Figure 4B, part-activated sequences (GAS) (Decker et al., 1991; Lew
et al. 1991). We therefore investigated whether the ability A). Following treatment of these cells with IFN-, as
expected, STAT1 translocates into the nucleus (Figureof BZLF1 to disrupt IFN--induced gene expression (Fig-
ure 1) is due to a defect in IFN--induced STAT1 tyrosine 4B, part F). The expression of wild-type BZLF1 (Figure
4B, part B) inhibits STAT1 nuclear translocation inducedphosphorylation in HeLa cells (Figures 2A and 2B) and
A549 cells (Figure 2C). Using an antibody that specifi- by IFN- (Figure 4B, part G, arrows). Deletion of the first
BZLF1 Inhibits IFN- Signaling
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Figure 1. BZLF1 Expression Inhibits IFN--
Induced IRF-1 and p48 Expression
HeLa cells and A549 cells were mock infected
or infected with an adenovirus (moi of 50)
expressing either LacZ or BZLF1.
(A) The level of cellular BZLF1 expression was
determined by FACS analysis in HeLa cells
infected with AdlacZ or AdZ, and EBV-posi-
tive gastric carcinoma cells (AGS-EBV),
which have approximately 5% of cells ex-
pressing BZLF1.
(B) Forty-eight hours postinfection, cells were
untreated or treated with 100 IU/ml IFN- for
24 hr. Immunoblot analyses were performed
with anti-IRF-1, anti-p65, or anti-p48 antibod-
ies. Membranes were reprobed with anti--
actin to control for protein loading
24 amino acids of BZLF1, previously shown to have a BZLF1 Reduces Tyrosine Phosphorylation
of Jak1 and Jak2replication function (Sarisky et al., 1996) and contain the
site for SUMO-1 modification (Adamson and Kenney, Due to our observations that BZLF1 inhibits both STAT1
tyrosine phosphorylation and nuclear translocation in-2001), does not affect its ability to inhibit IFN--induced
STAT1 nuclear translocation (Figure 4B, part C and 4B, duced by IFN-, we examined the upstream compo-
nents of the signaling pathway: Jak1 and Jak2 (Silven-part H). However, deletion of amino acids 1–86, which
include the transactivation domain, renders BZLF1 un- noinen, et al. 1993). The Jak1 and Jak2 tyrosine kinases
are associated with the cytoplasmic tails of the IFN-able to inhibit STAT1 nuclear translocation induced by
IFN- (Figure 4B, part D and 4B, part I). A BZLF1 mutant R and the IFN-R subunits, respectively (Bach et al.,
1997). Once activated, the Jak kinases phosphorylateunable to bind DNA due to a single amino acid change
at residue 185 in the DNA binding domain is also unable STAT1 molecules bound to a single phosphotyrosine on
the IFN-R subunit. We performed immunoprecipita-to inhibit IFN--induced STAT1 nuclear translocation
(Figure 4B, part E and 4B, part J). Therefore, both the tion of Jak1 (Figure 5A) and Jak2 (Figure 5B) with HeLa
cell extracts that had been mock infected or infectedtransactivation domain and the DNA binding domain are
necessary for BZLF1 to inhibit IFN--induced STAT1 with either AdlacZ or AdZ. The total levels of Jak1 in
AdZ infected cells was similar to Jak1 levels in bothnuclear translocation. These results indicate that BZLF1
inhibition of IFN- signaling may be secondary to a tran- mock-infected and AdlacZ-infected cells. The levels of
Jak2 in AdZ-infected cells also remained unchangedscriptional effect.
Immunity
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et al., 1997). We therefore examined the effect of BZLF1
on expression of the IFN-R subunit. We performed
immunoprecipitation of IFN-R with HeLa cell extracts
followed by immunoblot with anti-IFN-R antibody
(Figure 6A). Cells infected with AdZ had lower levels of
immunoprecipitated IFN-R than both mock-infected
and AdlacZ-infected cells. We also observed decreases
of IFN-R by direct immunoblot of AdZ-infected A549
cells (Figure 6B) as well as AdZ-infected normal human
fibroblasts (Figure 6C). From these experiments, we
conclude that BZLF1 inhibits IFN--induced signal
transduction and resultant gene expression by decreas-
ing the level of the  subunit of the IFN- receptor, the
site of both ligand binding and STAT1 docking.
IFN-R RNA Level Is Decreased by BZLF1
To further investigate the mechanism by which BZLF1
decreases the level of IFN-R, we examined whether
BZLF1 decreases the RNA level of the receptor subunit.
We expressed BZLF1 in HeLa cells and performed
Northern analysis on total RNA using a probe for the
IFN-R subunit (Figure 6D). The level of IFN-R RNA
in cells that expressed BZLF1 was greatly decreased in
comparison to cells that expressed the control protein
LacZ- and mock-infected cells. In contrast, the level of
GAPDH RNA was unaffected.
IFN--Induced MHC Class II Expression
Is Inhibited by BZLF1
A key downstream effect of IFN- signaling is the induc-
tion of class II expression in cells not normally express-
ing class II, thereby allowing cells to present viral anti-
gens to CD4 cells (Boehm et al., 1997). To determine
if BZLF1 prevents this critical aspect of IFN- signaling,
normal human fibroblasts were either mock infected,
AdlacZ infected, or AdZ infected. Two days after infec-
tion, a portion of the cells were treated with IFN- for
48 hr. Fibroblasts do not constitutively express MHC
class II but can be induced by IFN- to express MHC
class II (Collins et al., 1984; Pober et al., 1983). Flow
cytometry analysis of HLA-DR surface expression dem-
onstrated that IFN- induced MHC class II expression
on both mock-infected and AdlacZ-infected fibroblasts
Figure 2. BZLF1 Expression Inhibits IFN--Induced STAT1 Tyrosine (Figure 7A). In contrast, the ability of IFN- to stimulate
Phosphorylation MHC class II expression was almost completely abro-
HeLa cells (A and B), A549 cells (C), and Saos-2 cells (D) were mock gated in cells containing BZLF1. These results demon-
infected or infected with an adenovirus expressing either LacZ or
strate that BZLF1 expression inhibits IFN- induction ofBZLF1. Forty-eight hours postinfection, cells were untreated or
MHC class II surface expression, a major immunomodu-treated with 100 IU/ml IFN- for 30 min. Immunoblot analysis was
latory function.performed with an antibody that specifically recognizes only STAT1
phosphorylated on tyrosine 701 (upper panels) or an antibody that The expression of class II MHC is regulated by the
recognizes total STAT1 (lower panels). The IFN--induced increase class II transactivator (CIITA) (Steimle et al., 1993). Spe-
in STAT1 tyrosine phosphorylation was quantitated from three sepa- cifically, the IFN- induction of CIITA occurs through the
rate experiments in HeLa cells (B) using laser densitometry analysis.
activation of two CIITA promoters, III and IV (Harton
and Ting, 2000). RT-PCR analysis of CIITA transcripts
derived from the IFN--inducible promoters of CIITArelative to mock-infected and AdlacZ-infected cells.
However, IFN- induction of the activated (tyrosine demonstrated that expression of BZLF1 inhibits the abil-
ity of IFN- to upregulate CIITA expression (Figure 7B).phosphorylated) forms of Jak1 and Jak2 was reduced in
the AdZ-infected cells in comparison to AdlacZ-infected In contrast, IFN--induced CIITA expression from pro-
moters III and IV in cells expressing LacZ. CIITA pro-cells (Figures 5C and 5D).
moter I is not expressed in fibroblasts and is not IFN-
responsive (Figure 7B). Thus, expression of BZLF1 inhib-BZLF1 Decreases Expression of the IFN-R Subunit
IFN- initiates signaling by binding high-affinity sites on its IFN- induction of the class II master regulator CIITA,
which is essential for MHC class II gene expression.the extracellular domain of two IFN-R subunits (Bach,
BZLF1 Inhibits IFN- Signaling
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Figure 3. IFN--Induced STAT1 Tyrosine
Phosphorylation Is Specifically Inhibited by
BZLF1
(A) HeLa cells were mock infected or infected
with an adenovirus expressing either LacZ or
BZLF1. Forty-eight hours postinfection, cells
were treated with 500 IU/ml IFN- for 30 min.
Immunoblot analysis was performed with an
anti-phopsho-STAT1 (tyrosine 701) antibody.
(B) HeLa cells were infected with an adenovi-
rus expressing either LacZ or BRLF1. In the
upper panel, cells were untreated or treated
with either 500 IU/ml IFN- or 100 IU/ml IFN-
for 30 min. In the lower panel, cells were
treated with IFN- (100 IU/ml) for 24 hr. Immu-
noblot analyses were performed using anti-
phospho-STAT1 (upper panel) or anti-IRF-1
(lower panel) antibodies. The blot was re-
probed with an antibody that recognizes the
BRLF1 protein in the upper panel.
Discussion important IFN--responsive genes such as CIITA, IRF-1,
and p48, by decreasing the cellular level of the ligand
binding subunit of the IFN- receptor (IFN-R). OurIFN- plays an essential role in the regulation of the
immune system and the control of many different infec- findings, together with previous reports documenting
the inhibition of IFN--induced MHC class II expressiontious diseases, including herpesvirus infections. In vivo
studies have clearly established a protective role for by lytic viral proteins of Varicella-Zoster virus (VZV) (Ab-
endroth et al., 2000) and Cytomegalovirus (CMV) (HeiseIFN- in controlling acute murine cytomegalovirus
(MCMV) infection (Gribaudo et al., 1993; Lucin et al., et al., 1998; Miller et al., 1998; Sedmak et al., 1994),
suggest that inhibition of MHC class II expression may1994; Orange et al., 1995). In addition, IFN-/ mice and
IFN-R/ mice are more susceptible to MCMV infection be universally important for successful herpesvirus in-
fection.(Presti et al., 1998) as well as infection with herpes sim-
plex virus Type I (HSV-1) (Bouley et al., 1995; Cantin et It is noteworthy that one of the downstream targets
of BZLF1 is the CIITA protein, which is a master regulatoral., 1999). In this paper, we demonstrate that the EBV
immediate-early protein, BZLF1, inhibits IFN--induced of all class II MHC genes (Steimle et al., 1993) in addition
to other antigen processing molecules such as the In-MHC class II expression as well as the induction of other
Immunity
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Figure 4. BZLF1 Domains Required for Inhi-
bition of IFN--Induced STAT1 Nuclear
Translocation
(A) Structures of the wild-type and mutant
BZLF1 proteins. The transactivator domain
(TA), DNA binding domain (DNA), and dimer-
ization domain (DIM) are indicated along with
the respective amino acid numbers.
(B) HeLa cells were transfected with vector
control (A and F), wild-type BZLF1 (B and G),
BZLF1 25-245 (C and H), BZLF1 86-245 (D
and I), or BZLF1 A185K (E and J) plasmid
DNA. Forty-eight hours posttransfection,
cells were treated with 200 IU/ml IFN- for
30 min. Cells were stained with anti-BZLF1
(mouse monoclonal) and anti-STAT1 (rabbit
polyclonal) antibodies. BZLF1 staining is
shown in (B–E). STAT1 staining is shown in
(A and F–J). The arrows indicate the BZLF1-
transfected cells.
BZLF1 Inhibits IFN- Signaling
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Figure 5. BZLF1 Reduces Tyrosine Kinase
Phosphorylation of Jak1 and Jak2
(A) HeLa cells were mock infected or infected
with an adenovirus expressing either LacZ or
BZLF1. Forty-eight hours postinfection, cells
were treated with 100 IU/ml IFN- for 30 min
and harvested, and immunoprecipitation was
performed with either anti-Jak1 (rabbit poly-
clonal) antibody or rabbit IgG control anti-
body. Immunoblot analysis was performed
with anti-Jak1 antibody.
(B) HeLa cells were infected as in (A). Forty-
eight hours postinfection, cells were har-
vested and immunoprecipitation performed
with anti-Jak2 (rabbit polyclonal) antibody or
rabbit IgG control antibody. Immunoblot
analysis was performed with anti-Jak2 an-
tibody.
(C) HeLa cells were infected as in (A), immu-
noprecipitated using anti-Jak1 or rabbit con-
trol antibody, then probed with an anti-phos-
photyrosine antibody.
(D) HeLa cells were infected as in (A). Forty-
eight hours postinfection, cells were treated
with 1500 IU/ml IFN- for 5 min and har-
vested, and immunoblot analysis was per-
formed with anti-phospho-Jak2 antibody (up-
per panel) or anti--actin antibody (lower
panel).
variant chain and DM molecules (Harton and Ting, 2000). Expression of BZLF1 is sufficient to induce the lytic
form of EBV replication, and the BZLF1 transactivationBy affecting both promoters III and IV of CIITA, BZLF1
essentially shuts down the transcription of all IFN-- function is required for expression of many EBV early
genes. The protein also plays an essential role in replica-inducible class II MHC expression, and hence the activa-
tion of T helper cells required to initiate an immune tion by binding the lytic origin of replication (oriLyt)
(Chang et al., 1990; Fixman et al., 1992, 1995; Schepersresponse. This provides a clever and significant circum-
vention of the immune response. et al., 1993). However, increasing evidence demon-
strates that BZLF1 has a variety of other functions thatBZLF1 is a transcriptional transactivator that binds
AP-1-like sites (Farrell et al., 1989, Urier et al., 1989). alter the host cell environment, presumably to promote
Immunity
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Figure 6. BZLF1 Expression Decreases IFN-
R Protein Levels and RNA Levels
HeLa cells (A) were mock infected or infected
with an adenovirus expressing either LacZ or
BZLF1. Forty-eight hours postinfection, the
cells were treated with 100 IU/ml IFN- for 30
min and harvested, and immunoprecipitation
performed with anti-IFN-R antibody (rabbit
polyclonal) or anti-Jak2 antibody (rabbit poly-
clonal) as a control. Immunoblot analysis was
performed with anti-IFN-R antibody.
A549 cells (B) and normal human fibroblasts
(C) were infected in two separate experiments
as described in (A). Forty-eight hours postin-
fection, a portion of the cells were treated
with 200 IU/ml IFN- for 6 hr and harvested,
and immunoblot analysis performed with
anti-IFN-R antibody or anti--actin anti-
body.
(D) Total RNA was extracted from HeLa cells,
and Northern blot analysis was performed
with a probe specific for IFN-R mRNA (2.3
kb). Membranes were rehybridized with a
probe specific for GAPDH to control for equal
RNA loading.
the lytic replication cycle. For example, BZLF1 mediates Flemington, 1995) and has recently been shown to in-
duce dispersion of nuclear PML bodies which are be-cellular growth arrest (Cayrol and Flemington, 1996),
interacts directly with p65 (Gutsch et al., 1994) and p53 lieved to have antiviral functions (Adamson and Kenney,
2001). Here, we report that BZLF1 inhibits the IFN-(Zhang et al., 1994), alters CBP function (Adamson and
Kenney, 1999), and activates the p38 kinase and c-Jun signaling cascade, providing further evidence that the
protein plays a major role in viral subversion of hostN-terminal kinase signaling pathways (Adamson et al.,
2000). Additionally, BZLF1 induces the expression of immune responses.
Our findings reveal a new strategy among the herpes-the immunosuppressive cytokine TGF-1 (Cayrol and
BZLF1 Inhibits IFN- Signaling
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Figure 7. IFN--Stimulated MHC Class II Ex-
pression Is Inhibited by BZLF1
(A) Normal human fibroblasts were mock in-
fected or infected with an adenovirus ex-
pressing either LacZ or BZLF1. Forty-eight
hours postinfection, cells were untreated or
treated with 200 IU/ml IFN- for 48 hr. Cells
were stained with PE-labeled anti-HLA-DR
antibody or an isotype IgG2a-PE conjugate
and analyzed by fluorescence-activated flow
cytometry.
(B) Normal human fibroblasts were infected in
two separate experiments with an adenovirus
expressing either LacZ or BZLF1. Forty-eight
hours postinfection, cells were untreated or
treated with 200 IU/ml IFN- for 6 hr. RT-PCR
analysis was performed with primers specific
for CIITA transcripts from CIITA promoters I,
III, and IV or with primers for GAPDH.
viruses for inhibition of IFN--stimulated signal trans- transactivation (Heise et al., 1998). The specific VZV or
CMV protein(s) responsible for the inhibition of IFN-duction. VZV infection reduces the protein levels of
STAT1 and Jak2 (Abendroth et al., 2000), whereas HCMV signaling have not been identified, although the inhibi-
tion was found to occur during the lytic replication cycleinfection induces increased degradation of Jak1 (Miller
et al., 1998). In contrast, MCMV inhibition of IFN-- of these viruses and, in the case of HCMV, was found
to be due to the expression of immediate-early or earlyinduced signal transduction occurs downstream of
STAT1 phosphorylation, nuclear translocation, and viral gene products (Miller et al., 1998). In contrast to
Immunity
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the effects of HCMV and VZV, we found no effect of ally, EBV encodes an IL-10 homolog (BCRF1) that inhib-
BZLF1 expression on the protein levels of STAT1, Jak1, its production of IFN- by lymphocytes and IL-12 pro-
or Jak2. However, both IFN--induced STAT1 tyrosine duction by macrophages (Cohen, 1999), as well as a
phosphorylation and nuclear translocation are inhibited soluble receptor for colony-stimulating factor 1 (CSF-1),
by BZLF1, indicating a loss of signal upstream in the BARF1, that inhibits macrophage proliferation (Strock-
pathway. Consistent with this, we found that BZLF1 bine et al., 1998). These proteins likely function synergis-
expression decreases both the RNA and protein levels tically with BZLF1 to subvert the host immune response
of the IFN-R subunit, resulting in reduced Jak1 and and enhance viral replication. The BARF1 gene product
Jak2 tyrosine phosphorylation. Interestingly, IFN-R/ is expressed early in EBV replication (Strockbine et al.,
mice are more susceptible to HSV-1 infection than IFN- 1998), whereas both the BZLF2 and BCRF1 gene prod-
/ mice (Cantin et al., 1999), suggesting that an addi- ucts are expressed only late during EBV replication
tional ligand may exist for the IFN-R which also medi- (Kieff, 1996). In contrast, BZLF1 is an immediate-early
ates antiviral effects. Thus, the loss of IFN-R induced gene whose expression may provide the virus with initial
by BZLF1 may be an efficient mechanism by which the protection from antiviral defenses. We speculate that
virus can escape multiple antiviral responses of the host. further investigation of the role of EBV immediate-early
Mutational analysis of BZLF1 revealed that the first and early proteins in virus-immune system interactions
85 amino acids (which contain the transactivation do- will continue to reveal additional strategies for EBV eva-
main) as well as the DNA binding domain are required sion of the host immune response.
for the inhibition of IFN--induced STAT1 nuclear trans-
location. The amino-terminal half of BZLF1 (containing Experimental Procedures
the transactivation domain) has previously been shown
Cell Cultureto be required for the interaction of BZLF1 with the
HeLa, a cervical carcinoma cell line, and A549, a lung carcinomahistone acetylase CREB binding protein (CBP) (Adam-
cell line, were maintained in Dulbecco’s modified Eagle’s mediumson and Kenney, 1999). CBP regulates transcription by
H supplemented with 10% fetal bovine serum (FBS), 100 U/ml peni-
conformational alteration of chromatin and BZLF1 inter- cillin, and 100 	g/ml streptomycin. Saos-2 is an osteosarcoma cell
action with CBP inhibits transcriptional activation by line that was maintained in McCoy’s 5A medium supplemented with
CBP in promoters that do not contain BZLF1 binding 10% FBS. Normal human foreskin fibroblasts (NHF5-neo), a gift from
William Kaufmann at UNC Chapel Hill, were maintained in Eagle’ssites (Adamson and Kenney, 1999). The interaction be-
minimal essential media (GIBCO-BRL) supplemented with 10% FBStween BZLF1 and CBP might thus explain the decrease
and nonessential amino acids. The AGS-EBV cell line (a gift fromin IFN-R RNA levels found in cells expressing BZLF1.
Lindsey Hutt-Fletcher) was obtained by G418 selection of AGS cells
However, DNA binding mutants of BZLF1 are able to (a gastric carcinoma line) that were infected with a recombinant
associate with CBP, whereas we have found that a Akata virus in which a neomycin resistance cassette had been in-
BZLF1 DNA binding mutant (ZA185K) is unable to inhibit serted into the nonessential BDLF3 open reading frame and was
maintained in Ham’s F-12 medium with 10% FBS and 400 	g/mlIFN--induced STAT1 nuclear translocation. We hypoth-
G418. All cell lines were cultured at 37
C in a 5% CO2 incubator.esize instead that BZLF1 may bind to and activate the
promoter of a gene that encodes a repressor of IFN-
Adenovirus Construction and InfectionR gene expression. However, direct binding of BZLF1
The EBV IE genes BZLF1 and BRLF1 and the control lacZ gene,to the IFN-R promoter and prevention of expression
under control of the IE CMV promoter, were inserted via cre-loxP-
cannot be ruled out as a potential mechanism. mediated recombination into an adenovirus type 5 derivative lacking
Interestingly, expression of BZLF1 has no consistent the E1 and E3 genes to create adenovirus-LacZ (AdlacZ), adenovi-
effect on STAT1 tyrosine phosphorylation induced by rus-BZLF1 (AdZ), and adenovirus-BRLF1 (AdR), as previously de-
scribed (Westphal et al., 1999). Virus stocks were grown on the 293IFN-, indicating that the upstream components of this
cell line and purified by double cesium chloride gradient followedpathway (Tyk2, Jak1, and the IFN-R subunits) (Stark
by dialysis. HeLa, A549, and Saos-2 cell lines were plated at aet al., 1998) remain intact in cells expressing BZLF1.
density of 3.0  106 cells per 150 mm plate 24 hr prior to infection.However, these results do not rule out the possibility
Cells were infected with no adenovirus (mock infection), AdlacZ, or
that BZLF1 may inhibit IFN- responses downstream AdZ at a multiplicity of infection of 50.
of STAT1 activation. Indeed, our findings that BZLF1
inhibits IFN- induction of p48 (Boehm et al., 1997) (a key Transfection and Plasmids
component of the IFN--induced DNA binding complex) Cells were transfected with 5 	g of plasmid DNA by electroporation
indicates that at least some IFN--responsive genes are with 1500 V from a Zapper electroporation unit (Medical Electronics
Shop, University of Wisconsin). Wild-type BZLF1 expression vectorsalso likely inhibited by BZLF1. Additionally, expression
contain either the BZLF1 genomic sequence inserted in the pSG5of another EBV immediate-early protein, BRLF1, had no
expression vector (Stratagene) under the control of the simian viruseffect on STAT1 tyrosine phosphorylation induced by
40 (SV40) promoter (a gift from Diane Hayward), or a BZLF1 cDNA
either IFN- or IFN-. Taken together, these results sug- inserted into the pHD1013 under the control of the CMV IE promoter
gest BZLF1 has evolved a mechanism to specifically as previously described (Kenney et al., 1989). The ZA185K vector
inhibit the ability of host cells to respond to IFN-. contains a mutation in the DNA binding domain of BZLF1 in which
In summary, we have documented a unique strategy amino acid 185 has been altered from alanine to lysine (A185K),
abolishing DNA binding activity (Giot, et al., 1991). BZLF1 86-245among the herpesviruses to inhibit the cellular re-
(previously referred to as RAZR) has a deletion of amino acidssponses to IFN- and have identified the specific viral
2–85 (a gift of Joseph Pagano) (Furnari et al., 1994), and BZLF1 25-protein responsible. This study adds BZLF1 to a growing
245 has a deletion of the codons for the first 24 amino acids of
list of EBV proteins that modulate the immune response BZLF1 (Askovic and Baumann, 1997). ZA185K and BZLF1 86–245
during the lytic form of infection. The EBV glycoprotein, are in the pHD1013 vector, whereas BZLF1 25-245 is in the SG5
BZLF2, binds to the HLA-DR-chain of class II MHC and vector. Appropriate vector controls and wild-type BZLF1 controls
were included in each experiment.may disrupt its function (Spriggs et al., 1996). Addition-
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Immunoblot Analysis FBS and resuspended in 1 ml PBS. Stained cells were analyzed
using a FACScan analytical flow cytometer (Becton Dickinson). TheImmunoblot analysis of total cell extracts or immunoprecipitates
was performed as previously described (Adamson and Kenney, level of cellular BZLF1 expression was determined by fixing cells in
60% acetone, then incubating with Argene anti-BZLF1 antibody1999) with the following antibodies: anti-p48 (1:200), anti-IRF1
(1:200), anti-STAT1 (1:500), anti-phosphoSTAT1 (Tyr701) (1:200), (1:100; Argene), followed by FITC-conjugated anti-mouse antibody
(1:100; Sigma).anti-Jak1 (1:200), anti-Jak2 (1:200), anti-IFNR (1:200), anti-p65
(1:500) (all from Santa Cruz), anti-phospho-Jak2 (Y1007, Y1008)
(1:400; UBI), anti--actin mouse monoclonal (1:5000; Sigma), anti- Acknowledgments
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